Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Tw1st3d1r0non Feb 18, 2021 7:13am

119 Views

Post# 32593310

PLAN B

OnLyFaNs.com/RoBeRtFaRrElL/

We want to see results we want our money back! Yes we risked it but you have also fooled us into a product you aren't delivering! Where's the damn press release? Get your ar$e shaking asap...investors aren't too damn happy if you've noticed!

<< Previous

Bullboard Posts

Next >>

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi